BBP.US Virtus LifeSci Biotech Products ETF
- Total assets
- 135M
- Expense ratio
- 0.77%
- Dividend yield
- -
- 1-year return
- +35.57%
- Holdings
- 65
- Since
- 2014
Fund data as reported by the issuer, updated Nov 14, 2026. Total assets are in the fund's base currency.
What does BBP.US invest in?
- Mostly US stocks (96.6%)
- Largest sector: Healthcare (100.0%)
- Largest region: North America (98.8%)
- Top 3 holdings: 12.5% of the fund
Asset allocation
- US stocks 96.6%
- Non-US stocks 4.8%
- Cash 0.2%
Top holdings
- Moderna Inc 6.64%
- Xeris Pharmaceuticals Inc 2.98%
- Verastem Inc 2.85%
- Omeros Corporation 2.53%
- Iovance Biotherapeutics Inc 2.53%
Virtus LifeSci Biotech Products ETF performance
Sharpe ratio 1.27- This year
- +31.02%
- 1 year
- +35.57%
- 3 years
- +30.47%
- 5 years
- +16.40%
Volatility 17.2% over 1 year and 17.9% over 3 years. Moderate, similar to a broad stock index.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
BBP.US price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About Virtus LifeSci Biotech Products ETF
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration (FDA) for marketing.
Full fund profileVirtus LifeSci Biotech Products ETF top holdings
27.7% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Moderna Inc MRNA.US | Healthcare | United States | 6.64% |
| Xeris Pharmaceuticals Inc XERS.US | Healthcare | United States | 2.98% |
| Verastem Inc VSTM.US | Healthcare | United States | 2.85% |
| Omeros Corporation OMER.US | Healthcare | United States | 2.53% |
| Iovance Biotherapeutics Inc IOVA.US | Healthcare | United States | 2.53% |
| Kiniksa Pharmaceuticals Ltd KNSA.US | Healthcare | United States | 2.34% |
| BeiGene Ltd BGNE.US | Healthcare | United States | 2.05% |
| ADMA Biologics Inc ADMA.US | Healthcare | United States | 2.01% |
| Zai Lab Ltd ZLAB.US | Healthcare | United States | 1.93% |
| Regeneron Pharmaceuticals Inc REGN.US | Healthcare | United States | 1.86% |
The 10 largest of 65 holdings.
BBP.US sector exposure
- Healthcare100.0%
Share of the stocks in the fund.
BBP.US regional exposure
- North America98.8%
- Asia Emerging2.1%
- United Kingdom1.9%
- Europe Developed1.2%
Share of the stocks in the fund.
Company size
Average market cap 7.76B- Big cap8.9%
- Medium cap21.9%
- Small cap27.4%
- Micro cap36.2%
Virtus LifeSci Biotech Products ETF fund profile
- Fund name
- Virtus LifeSci Biotech Products ETF
- Ticker
- BBP.US
- Exchange
- USA Stocks
- Issuer
- Virtus
- Index tracked
- -
- Category
- Healthcare Equity
- Domicile
- United States
- Inception date
- Dec 16, 2014
- Trading currency
- USD
- Expense ratio
- 0.77%
- Annual turnover
- 0.5%
About Virtus LifeSci Biotech Products ETF
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration (FDA) for marketing.